Abbott’s neuromodulation systems can significantly reduce pain-related healthcare visits for people living with chronic pain, according to five-year data.
ABBOTT PARK, Ill., May 16, 2023 /PRNewswire/ -- Abbott announced today that the U.S. Food and Drug Administration (FDA) has approved its spinal cord stimulation (SCS) devices for the treatment of ...
Two years after implant, patients who use Abbott Laboratories' implantable spinal cord stimulators for chronic pain continue to prefer the company's proprietary stimulation pattern over traditional ...
Spinal cord stimulation (SCS) therapies for chronic back and/or leg pain is superior to conventional medical management (CMM) for reduced pain intensity and functional disability, new research ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results